---
title: Volume Responsiveness Assesment After Propofol.
nct_id: NCT03917446
overall_status: COMPLETED
sponsor: Medical University of Gdansk
study_type: OBSERVATIONAL
primary_condition: Circulatory Failure
countries: Poland
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03917446.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03917446"
ct_last_update_post_date: 2022-07-15
last_seen_at: "2026-05-12T07:00:54.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Volume Responsiveness Assesment After Propofol.

**Official Title:** Prediction of Volume Responsiveness After Propofol Bolus Injection in the Intensive Care Unit (ICU) Patients.

**NCT ID:** [NCT03917446](https://clinicaltrials.gov/study/NCT03917446)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** Medical University of Gdansk
- **Conditions:** Circulatory Failure, Fluid Volume Disorder, Critical Illness
- **Start Date:** 2017-09-01
- **Completion Date:** 2020-09-01
- **CT.gov Last Update:** 2022-07-15

## Brief Summary

Patients in ICU who suffer from circulatory insufficiency, regardless the cause that require invasive hemodynamic monitoring. The aim of the study is to correlate stroke volume variation which predicts fluid responsiveness with change of the blood pressure after intravenous admission of propofol. This test could become a surrogate of stroke volume variation in patients with contraindications to minimally invasive hemodynamic monitoring.

## Detailed Description

This prospective, observational study was conducted after approval of the Independent Bioethics Commitee at Medical University of Gdańsk (numer zgody) and registered in ClinicalTrials.gov. Mechanically ventilated patients of intensive care unit who routinely recieved haemodynamic monitoring with PiCCO™ (Getinge AB, Sweden) technology using Philips IntelliVue PiCCO-Module (Philips Healthcare, Amsterdam, Netherlands), were enrolled. Patients were sedated with midazolam infusion at 0,15 to 0,6 mg kg-1 h-1 . Before the trial in each patient, heart rate (HR) invasive (IBP) and non - invasive blood pressure, (NIBP) infusion rate of catecholamines and non adrenergic vasopressors was recorded and PiCCO device was callibrated by transpulmonary thermodilution with 20 ml of cold saline. Global end diastolic volume (GEDV), intrathoracic blood volume (ITBV) and stroke volume variation (SVV) were calculated and recorded. For effective ventilation with increased tidal volume of 8 ml kg-1 of Predicted Body Weight, each patient recieved propofol bolus of 0,25 mg kg-1, 0,5 mg kg-1 and 1,0 mg kg-1 consecutively. Higher doses were used at good tolerance of the lower ones. After each bolus systolic and diastolic invasive blood pressure, heart rate (HR), continuous cardiac output (CCO), continuous cardiac index (CCI), stroke volume index (SI), stroke volume variantion (SVV), and left ventricular contractility index (dPmax) were recorded every fifteen seconds for ten minutes. The absolute and realtive change in blood pressure, compared to the values of blood pressure before the drug administration, were correlated with SVV. Time interval between each examination ranged from 4 to 48 hours.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

ICU patient Haemodynamically instable Mechanically ventilated

Exclusion Criteria:

Simultaneous propofol infusion Contraindications for propofol Atrial fibrillation Valvular malfunction Aortic stenosis Aortic aneurysm
```

## Arms

- **Euvolaemic** — Patients with stroke volume variation less than 8%
- **Hypovolaemic** — Patients with stroke volume variation greater than 13%

## Interventions

- **Propofol bolus** (DRUG) — Each patient gets propofol bolus in three doses. 0.25 mg/kg, 0.5 mg/kg and 1 mg/kg. After each dose patient's blood pressure, heart rate and haemodynamic values calibrated with PICCO device (cardiac output, cardiac index, stroke index, stroke volume, stroke volume variation, dPmax) are recorded in 15 seconds intervals for 10 minutes.

## Primary Outcomes

- **Blood pressure** _(time frame: 10 minutes)_ — Change in blood pressure values after propofol bolus.
- **Heart rate** _(time frame: 10 minutes)_ — Change in heart rate values after propofol bolus.
- **Cardiac output** _(time frame: 10 minutes)_ — Change in cardiac output values after propofol bolus.
- **Cardiac index** _(time frame: 10 minutes)_ — Change in cardiac index values after propofol bolus.
- **Stroke volume** _(time frame: 10 minutes)_ — Change in stroke volume values after propofol bolus.
- **Stroke index** _(time frame: 10 minutes)_ — Change in stroke index values after propofol bolus.
- **Stroke volume variation** _(time frame: 10 minutes)_ — Change in stroke volume variation values after propofol bolus.
- **Maximum left ventricular contractility (dPmax)** _(time frame: 10 minutes)_ — Change in dPmax values after propofol bolus.

## Locations (1)

- Medical University of Gdańsk - Departament of Anesthesiology and Intensive Care, Gdansk, Poland

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.medical university of gdańsk - departament of anesthesiology and intensive care|gdansk||poland` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03917446.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03917446*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*